Changes have been made to the presentation outline - by the CEO...

Changes have been made to the presentation outline - by the CEO at this forthcoming conference.

It has been heavily toned down. I did think, it was fairly strong from the CEO and even the charity supporting GBM AGILE.

Fair enough and no big deal. Although I was previously complimentary of the CEO to maybe scrutinize GBM AGILE. All that is gone now, as you can see.


Instead of  this at the 9.30am timeslot. (from the first post on this Thread View

--------------------------------------------

James Garner Chief Executive OfficerKazia Therapeutics
David Arons Chief Executive Officer National Brain Tumor Society

9:30 Panel Discussion: GBM AGILE Goes Worldwide: Taking a Deep Dive Into How Well It Has Worked So
Far & What Promise It Brings With Expansion

• Reflecting on more than 3 years of GBM AGILE - lessons learned to date and plans/goals for the next 3+ years

• Pharma perspectives of participation and stakeholder perspectives

• Learning from an annotated longitudinal database of screens from over 1300 glioblastoma patients

• What progress have we already seen with GBM AGILE so far?

• Conceptually, a ‘master protocol’ requires a standardized trial design across all participating arms, with limited
ability to customize for specific agents. To what extent does that force compromise in the study design? Is there
a risk we end up with a study that isn’t ideally suited to any of its participating drugs?

• As a Bayesian adaptive study, participant companies in GBM AGILE are unable to know much about the ongoing
performance of the study until the study is complete. What are the implications of this, particularly for smaller biotechs?

• GBM AGILE sets pre-defined thresholds for graduation within the study and for successful completion at the end
of the study. How do we balance those thresholds such that we neither take forward ineffective therapies, nor
prematurely discard therapies that may prove beneficial to patients?

----------------------

We now have at 9.30am - a big modification. Sort of understand why?

9:30 am Panel Discussion: GBM AGILE – An Evergreen Registration Model for Evaluating New Treatments for GBM

• James GarnerChief Executive Officer, Kazia Therapeutics Limited
• David AronsChief Executive Officer, National Brain Tumor Society

Synopsis

• Reflecting on more than 3 years of progress – lessons learned to date and plans/goals for the next 3+ years
• Stakeholder perspectives – industry, clinical/scientific investigators, and patient advocates
• Adaptive Global Innovative Learning Environment (AGILE): Focusing on the “LE” in AGILE

------------------------------------------------------------------------------------------------------------------------------------

Alot different, as you can see.

But of more interest - and not previously mentioned, is this most interesting presentation, from the CEO, at the same conference.

This presentation would seem to discuss the Paxalisib study at Weill Connell . (Lewis Cantley previous hospital - he has moved to Dana Farber, to presumably further studies on PI3K)

Very hard to keep up with work is happening with this company.  I would love to hear what Patrick Wen has to say, in his update as to current GBM drugs in development.  (But hey SP halved  - and paxalisib really struggling in GBM AGILE) - completely untrue --my words


-----------------------------------------------------------
11:30 am PI3K Inhibition With Hypoinsulinaema – A Novel Approach to Maximizing the Impact of Targeted Therapy

• James GarnerChief Executive Officer, Kazia Therapeutics Limited

Synopsis

• Reviewing the role of the PI3K pathway in glioblastoma
• Evaluating the rationale for combining PI3K pathway inhibition with hypoinsulinaemia
• Overview of an ongoing clinical trial to explore the combination.